Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New Elite Feature:   Find Similar Charts in Seconds

Learn How
Market News Market Pulse Stocks News ETF News Crypto News

Actuate Therapeutics

Contributing Author

Recent Articles by Actuate Therapeutics

Sep-09
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference ACTU -8.03% ACTU -8.73% GlobeNewswire
Sep-09
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib ACTU -8.03% GlobeNewswire
Jun-09
Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma ACTU +10.44% GlobeNewswire
May-11
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program ACTU -9.85% GlobeNewswire
May-06
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors ACTU GlobeNewswire
Apr-14
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma ACTU +14.29% GlobeNewswire
Mar-09
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors ACTU GlobeNewswire
Mar-04
Actuate Therapeutics to Present at The Citizens Life Sciences Conference ACTU GlobeNewswire
Feb-24
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference ACTU +10.64% GlobeNewswire
Jan-21
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers ACTU +5.40% GlobeNewswire
Jan-12
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 ACTU -6.35% GlobeNewswire
Jan-06
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers ACTU +5.05% GlobeNewswire
Dec-18
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 ACTU GlobeNewswire
Dec-15
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma ACTU -8.78% GlobeNewswire
Sep-22
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months ACTU +6.78% GlobeNewswire
Sep-11
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option ACTU GlobeNewswire
Sep-10
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock ACTU -19.15% GlobeNewswire
Sep-09
Actuate Therapeutics Announces Proposed Public Offering of Common Stock ACTU +7.18% GlobeNewswire
Aug-06
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer ACTU +11.76% GlobeNewswire
Jul-17
Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas ACTU GlobeNewswire
Jun-24
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial ACTU GlobeNewswire
Jun-20
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO ACTU GlobeNewswire
Jun-16
Actuate Therapeutics Announces Inclusion in the Russell 3000 and Russell 2000 Indexes ACTU GlobeNewswire
Jun-02
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer ACTU -11.01% GlobeNewswire
May-31
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer ACTU GlobeNewswire
May-22
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer ACTU -8.01% GlobeNewswire
May-07
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting ACTU GlobeNewswire
May-06
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer ACTU -6.88% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)